NCT02662634

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: GU Research Network, LLC · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.

Detailed description

Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer. Non-small cell lung cancer tumor will be resected from the patient. RNA from the tumor will be amplified and subsequently electroporated into matured, autologous dendritic cells. The dendritic cells with tumor RNA will be dosed back to the patient. Study will investigate feasibility and safety.

Conditions

• Non-small Cell Lung Cancer (NSCLC)

Interventions

Type	Name	Description
BIOLOGICAL	AGS-003-LNG	autologous dendritic cell immunotherapy
DRUG	Carboplatin	Carboplatin is an anticancer drug ("antineoplastic" or "cytotoxic") chemotherapy drug. Carboplatin is classified as an "alkylating agent."
DRUG	Abraxane	Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
DRUG	Alimta	By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
DRUG	Cisplatin	Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
DRUG	Taxol	Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
RADIATION	Radiation Therapy	Causes DNA strand breaks.

Timeline

• Start date: 2016-03-01
• Primary completion: 2018-03-01
• Completion: 2018-03-01
• First posted: 2016-01-25
• Last updated: 2022-03-18

Locations

1 site across 1 country: United States